PicoCELA Inc. (NASDAQ:PCLA) Short Interest Update

PicoCELA Inc. (NASDAQ:PCLA) was the target of a significant drop in short interest during the month of June. As of June 15th, there was short interest totaling 37,187 shares, a drop of 70.6% from the May 31st total of 126,693 shares. Currently, 93.0% of the company’s shares are sold short. Based on an average trading volume of 116,946 shares, the short-interest ratio is presently 0.3 days.

PicoCELA Stock Down 9.3%

Shares of PCLA stock traded down $0.65 during trading hours on Monday, reaching $6.33. The company had a trading volume of 283,843 shares, compared to its average volume of 821,956. The company has a 50 day moving average of $4.26 and a 200 day moving average of $4.78. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.57 and a current ratio of 2.13. PicoCELA has a 1-year low of $1.35 and a 1-year high of $112.20.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new stake in PicoCELA stock. XTX Topco Ltd bought a new position in shares of PicoCELA Inc. (NASDAQ:PCLA) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 44,648 shares of the company’s stock, valued at approximately $72,000. XTX Topco Ltd owned 0.16% of PicoCELA at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of PicoCELA in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.